Patents by Inventor Basant Kumar THAKUR

Basant Kumar THAKUR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection
    Patent number: 10844436
    Abstract: The present invention is directed to methods of prognosing, treating, or managing treatment of cancer in a subject. These methods involve selecting a subject having cancer, obtaining, from the selected subject, a sample containing exosomes, recovering the exosomes from the sample, and isolating the double-stranded DNA from within the exosomes. The isolated double-stranded DNA is then used to detect the presence or absence of one or more genetic mutations associated with cancer, quantify the amount of isolated double-stranded DNA from the recovered exosomes in the sample, detect the methylation status of the isolated double-stranded DNA, or quantify the amount isolated double-stranded DNA able to enter a recipient cell. The prognosing, treating, or managing treatment is carried out based on this information.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: November 24, 2020
    Assignees: CORNELL UNIVERSITY, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David C. Lyden, Hector Peinado Selgas, Haiying Zhang, Basant Kumar Thakur, Annette Becker, Jacqueline Bromberg
  • USE OF DOUBLE-STRANDED DNA IN EXOSOMES: A NOVEL BIOMARKER IN CANCER DETECTION
    Publication number: 20170175200
    Abstract: The present invention is directed to methods of prognosing, treating, or managing treatment of cancer in a subject. These methods involve selecting a subject having cancer, obtaining, from the selected subject, a sample containing exosomes, recovering the exosomes from the sample, and isolating the double-stranded DNA from within the exosomes. The isolated double-stranded DNA is then used to detect the presence or absence of one or more genetic mutations associated with cancer, quantify the amount of isolated double-stranded DNA from the recovered exosomes in the sample, detect the methylation status of the isolated double-stranded DNA, or quantify the amount isolated double-stranded DNA able to enter a recipient cell. The prognosing, treating, or managing treatment is carried out based on this information.
    Type: Application
    Filed: April 1, 2015
    Publication date: June 22, 2017
    Inventors: David C. LYDEN, Hector Peinado SELGAS, Haiying ZHANG, Basant Kumar THAKUR, Annette BECKER, Jacqueline BROMBERG